Hepatitis C Virus Viral Assays in the Direct-Acting Antiviral Era

Clinics in Liver Disease

Volumn 17, Issue 1, 2013, Pages 27-45

  Vierling, John M ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Genotype; Hepatitis C virus; Interleukin 28B; Limit of detection; Lower limit of quantification; Polymerase chain reaction; Resistance associated variants; Target not detected

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL THERAPY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; NONHUMAN; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERLEUKINS; LIMIT OF DETECTION; MEDICAL FUTILITY; POLYMERASE CHAIN REACTION; RNA, VIRAL; TERMINOLOGY AS TOPIC;

EID: 84870040222     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.09.002     Document Type: Review

References (46)

1. Bostan N., Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol 2010, 36:91-133.
2. Davis G.L., Alter M.J., El-Serag H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-521.
3. Angelico M. Epidemiology and outcome of hepatitis C relapse in transplant recipients. Transplant Proc 2011, 43:2457-2458.
4. Selzner N., Guindi M., Renner E.L., et al. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011, 55:207-217.
5. McHutchison J.G., Lawitz E.J., Shiffman M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
6. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
7. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
8. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
9. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
10. US Food, Drug Administration Antiviral drug advisory committee meeting and briefing materials for boceprevir 2011, US Food and Drug Administration.
11. US Food, Drug Administration Antiviral drug advisory board meeting and briefing materials for telaprevir 2011, US Food and Drug Administration.
12. Halfon P., Sarrazin C. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?. Liver Int 2012, 32(Suppl 1):79-87.
13. Cobb B, Pockros PJ, Vilchez RA, et al. HCV RNA viral load assessments in the era of direct acting antivirals. Am J Gastroenterol, in press.
14. Soriano V., Vispo E., Poveda E., et al. Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother 2012, 13:313-323.
15. Wedemeyer H., Jensen D.M., Godofsky E., et al. Recommendations for standardized nomenclature and definitions of viral response in trials of HCV investigational agents. Hepatology 2012, 10.1002/hep.25888.
16. Harrington P.R., Zeng W., Naeger L.K. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012, 55:1048-1057.
17. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
18. Burney T., Dusheiko G. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Expert Rev Anti Infect Ther 2011, 9:151-160.
19. Kadam J.S., Gonzalez S.A., Ahmed F., et al. Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin. Dig Dis Sci 2007, 52:2525-2530.
20. Morishima C., Morgan T.R., Everhart J.E., et al. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology 2008, 48:1412-1419.
21. Thadani A., Harley J., Rubin J., et al. Clinical significance of discordant positive hepatitis C virus transcription-mediated amplification following end of treatment response. Dig Dis Sci 2012, 57:239-242.
22. Abbott Real Time HCV PCR: PMA P100017 FDA summary of safety and effectiveness. 2011.
23. Victrelis (boceprevir) capsules. U.S. prescribing information 2011, Merck, Whitehouse Station (NJ).
24. Incivek (telaprevir) film coated tablets. US prescribing information 2011, Vertex Pharmaceuticals, Cambridge (MA).
25. New DAA FDA guidance. Available at: Accessed August, 2012. http://www.natap.org/2012/HCV/041012_03.htm.
26. Gambarin-Gelwan M., Jacobson I.M. Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors. Curr Gastroenterol Rep 2012, 14:47-54.
27. Susser S., Vermehren J., Forestier N., et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011, 52:321-327.
28. Jacobson I.M., Marcellin P., Zeuzem S., et al. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology 2012, 56:567-575.
29. Adda N, Bartels DJ, Gritz L, et al. Understanding futility rules in telaprevir combination treatment. Clin Gastroenterol Hepatol, in press.
30. Meyer S.D., Dierynck I., Ghys A., et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the realize trial. Hepatology 2012, 10.1002/hep.25962.
31. Rong L., Ribeiro R.M., Perelson A.S. Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull Math Biol 2012, 74:1789-1817.
32. Delang L., Vliegen I., Froeyen M., et al. Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication. Antimicrob Agents Chemother 2011, 55:4103-4113.
33. Imhof I., Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 2011, 53:1090-1099.
34. GenoSure. Available at: http://www.monogrambio.com/.
35. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
36. Thompson A.J. Genetic factors and hepatitis C virus infection. Gastroenterology 2012, 142:1335-1339.
37. Thomas D.L., Thio C.L., Martin M.P., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
38. Neukam K., Camacho A., Caruz A., et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol 2012, 56:788-794.
39. Cisneros E., Banos I., Citores M.J., et al. Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860. Transplantation 2012, 94:275-280.
40. Duarte-Rojo A., Veldt B.J., Goldstein D.D., et al. The course of post-transplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation 2012, 94:197-203.
41. Eurich D., Boas-Knoop S., Bahra M., et al. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and post-transplant antiviral therapy. Transplantation 2012, 93:644-649.
42. Fukuhara T., Taketomi A., Motomura T., et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010, 139:1577-1585.
43. Kawaoka T., Takahashi S., Takaki S., et al. IL28B SNP of donors and recipients can predict virological response to PEGIFN/RBV therapy in patients with recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol 2012, 27(9):1467-1472.
44. Lange C.M., Moradpour D., Doehring A., et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011, 55:322-327.
45. Motomura T., Taketomi A., Fukuhara T., et al. The impact of IL28B genetic variants on recurrent hepatitis C in liver transplantation: significant lessons from a dual graft case. Am J Transplant 2011, 11:1325-1329.
46. Zeuzem S., Andreone P., Pol S., et al. Realize trial final results: telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ribavirin. J Hepatol 2011, 54:S3. Ref type: abstract.